I am not a professional advisor. Seek professional advice before investing or trading.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well... there's that too :) Both theories reduce the "perceived pain" lol.
Good point... they may have pushed too hard... or had to rush the remaining shares out yesterday. Regardless... hopefully its over, we get an announcement today or tomorrow, and you buy me that beer ;)
Well... what I'm putting forth is:
1) gem did file a notice (I posted it a few minutes ago)
2) the prez was going to announce but had to wait, so a lame plasma announcement was released instead
3) gem finalized the dump and/or whatever other business stuff needed to be finalize
4) prez is now free to announce... tomorrow at the rnc or press conf???
(speculation / conspiracy theory)
Well... they didn't dump them all at once. It got trickled out. Gave people an opportunity to get out if they wanted, rather than slapping them down hard on the concrete. Perhaps they do have the investor's concern in mind.
The plasma announcement on Sunday just didn't make sense... it certainly didn't seem like a "breakthrough therapeutic". Total speculation, but is it possible the prez was planning on announcing Aviptadil (or other) as the "breakthrough therapeutic" on Sunday, but then needed to hold off for some reason (perhaps for some business deal to finalize or for rlftf/gem to finish dumping shares for funding purposes), so he had to go with a lame blood plasma announcement in the meantime?
Can someone help me accurately interpret this notice! Looks like it backs up the assumption.
https://www.ser-ag.com/en/resources/notifications-market-participants/official-notices.html#/notice-details/248681
Uncle Gee Gee
What will a RS do to us shareholders? And can you please comment on what you think a buyout with RS will do to us shareholders.
We had to get the Princeton Angels on board to fund the rest of the trials, so now that's out of the way :)
(Total speculation)
I'm calling 48 as the bottom (double bottom). I believe we go up from here. A break above .5151 would be solid confirmation.
(Total speculation)
Chart analysis... I'm looking at the 1hr chart. Uptrend support line from the top of Aug 3rd at 30c, then the bottoms of Aug 11 at 36c, Aug 12 at 38c, then Aug 13 at 38.50c, then today at 48c. We're forming a pendent, as there is another line coming from the tops. We're nearing the breakout point, which will happen today or tomorrow. Go bulls!
Double bottom at 48... she's gonna curl and rip up
Added at 4805... nice!
You are not alone. Twitterville agrees, and so do I.
Partnership:
Other than FDA approval, which news items do you think will have the greatest impact on $RLFTF stock price?
— Uncle Gee Gee (@UncleGeeGee) August 24, 2020
Where do you think $RLFTF stock price will end up by Dec 31st?
— Uncle Gee Gee (@UncleGeeGee) August 24, 2020
In layment terms... Vent is the machine that helps your lungs breath when you cant breath on your own. ECMO is the next stage when your lungs still can't produce enough oxygen in the blood even with the vent, so they pump your blood out of your body, add oxygen, and pump it back in. I'm sure a doc will correct my sloppy interpretation, but that's my basic understanding.
Shelly... you need to do some research. You need to understand what you own; otherwise you will have endless doubt about whether to sell or hold. If you do the research and dig into what's really going on here, you will become unshakable in your decision. Here's the bottom line... we are all waiting for the big news (FDA approval), because we believe we have the #1 covid treatment on the planet. It sounds hard to believe on a .50c to .60c penny stock (which is why dd-due dilligence- is necessary to build your confidence), but we think this is a unique, rare situation where a penny stock actually has the world's solution to covid. If so, this is the drug/solution/stock of the decade. Most people here are heavily vested, some are all-in. The magnitude of what we believe will be difficult for others to TRUST. How can you possibly trust a bunch of strangers on some website that looks like it was built in 1980? You do you're own due diligence... that's how. You will not see us sell our shares until FDA approves or denies. Until then, nothing else matters. Welcome and good luck!
Javitt never promised the partnership announcements would happen last week or this week. He simply said... "We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States and a partnership with a very large well-known public company that can get any drug to any hospital overnight.” That statement could mean the announcement is coming next month for all we know. I'm quite grateful he's given us that inside info. I wouldn't want him to shut his mouth. The guy is well-respected, well-connected, and I wouldn't want anyone else running the show.
I think Dr. Yo is only interested in RLFTF to make his RANTES point. His relationship with DR. Patterson is now very personal, since Yo is so vested in the RANTES connection (a possibly very important discovery), and Dr. Patterson is his partner on that. He doesn't really understand or care what is happening from an rlftf business perspective. He's not connecting all the rlftf dots yet. If he were, then he would have been more prepared to provide facts during the Dr. Drew interview... instead, he flopped when he was given the opportunity to discuss the pre-print results (or perhaps he deliberately chose not to). Now... he has done a lot to bring attention to rlftf, but only due to the RANTES connection. Regardless, I'm grateful for what he has done so far, I just think the Dr. Drew interview was a missed opportunity (for us).
Just a total guess, but maybe that's the tech company that will develop out the data capture solution that Dr. Javitt said he son came up with... where the nebulizer connects to the cloud via bluetooth to record when patients are taking the drug and monitoring vitals via a wristwatch for in-home patients. One possibility, but total speculation.
Trump knows some big drugs are about to come through: RLF-100 and the few other/lesser competitors, so he's priming the pump to make it look like he "unstuck the pipeline". Tonight was the beginning of a multi-play political stunt right before RNC. We should see a follow up on that strategy this week.
Kiwi... As for the financing to complete the trials, I would assume that has likely already been done with the "Princeton Angels" recently referenced in the pre-print (also the reason why we haven't heard anything from last weekend's meeting at UM). No worries on funding the trials... I think that's already done.
Also... I think Trump wants to announce Aviptadil at the RNC for the best bang. Besides... he needs more time to practice pronunciation :)
Uncle Gee Gee
Summary of known facts about RLFTF:
Aviptadil RLF-100 VIP
• Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.
Stock/Company
• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.
• Unconfirmed: Most of the outstanding shares are owned by insiders.
• Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.
Manufacturing and Distribution
• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt
Clinical Trials
• Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.
• Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.
• Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.
• Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
Official publication page 68...
https://relieftherapeutics.com/wp-content/uploads/2020/04/Relief-Full-Annual-Report-2019-Final.pdf
I have compiled a list of facts. Please let me know if I missed anything!
Aviptadil RLF-100 VIP
• Aviptadil is a repurposed erectile dysfunction drug, proven to be safe since 1970’s.
• Aviptadil blocks Covid from attaching to host cells in the lungs, prevents the cytokine storm, and reduces inflammation. This is a targeted trifecta for treating Covid.
• An inhaler version of Aviptadil will undergo clinical trials, with the intent to ultimately be used for in-home treatment of Covid cases. This study is expected to complete around Nov 31, with results being published sometime afterwards.
• Aviptadil is inexpensive and easy to manufacture.
• Aviptadil shows promise for other lung applications beyond Covid, which also needs to be studied and tested.
Stock/Company
• Relief Therapeutics holds the patent on Aviptadil. It is a small company in Switzerland, traded over the counter (OTC).
• NeuroRX is a private US-based partner with leadership that is well-connected at the highest levels of government and big pharma. They are guiding Relief Therapeutics through the FDA approval process.
• Company has $3M cash, but will need approx. another $20M to complete all 3 trials, including inhaler version.
• Unconfirmed: Most of the outstanding shares are owned by insiders.
• Chairman Raghuram (Ram) Selvaraju says there is no real need to raise capital via additional shares at this point, due to liquidity option provided by GEM.
• Speculation: Company may have recently raised enough additional capital to complete trials through Princeton Angels.
Manufacturing and Distribution
• Robert Bestoff, Chief of Operations, spent his career at Lilly & Pfizer. At Pfizer, he was head of entire neuro science and pain division and was responsible for $10b of drugs.
• Manufacturing program put together by Rich Siegel, former head of Johnson & Johnson’s drug portfolio.
• 2 Partnership arrangements are expected to be announced soon.
• “We are about to announce a partnership with the largest supplier of inhaled sterile drugs in the United States.” NeuroRX CEO Dr. Javitt
• “We are about to announce a partnership with a very large well-known public company that can get any drug to any hospital overnight” NeuroRX CEO Dr. Javitt
• “By October, we should be manufacturing enough drug for 100,000 people each month.” NeuroRX CEO Dr. Javitt
John... most of us here who are holding large positions understand the enormous opportunity we have before us. The stock will get a few bursts upward and fades down from day to day, and that may seem scary, but this stock will not take off until official news hits. Many people who are in for a get-rich scheme are expecting to get rich in a few days, and now that those few days have passed, they are getting nervous. Until public announcements are made, you won't see much price increase, but you will see fearful traders dropping out (the short-sighted are tripping over dollars to pick up pennies). I do pray for Captain Tommy, but people who are hanging their hat on 1 case don't understand the magnitude of what’s happening here.
We KNOW this drug is a golden unicorn based on the extraordinary results of the pre-print that we thankfully have had the opportunity to see. Think about the magnitude of a worldwide cure... the company needs time to get prepared and launch it properly... you don't just develop a drug and start making hundreds of millions of dollars right away... they have a lot of preparation, including political positioning and such. This is a worldwide solution, and a lot of wealth will be transferred as a result, so let’s let give the powerful individuals involved here the time they need to do this right. We don’t want them rushing into this… we have the cure, so let’s get it launched properly and professionally. If we get good news about the fireman, you’ll see some push up from the day traders, but that’s all irrelevant to what we are expecting upon the eventual official announcements that will hit all the investment outlets and public news outlets. It’s just a matter of time (probably longer than you expect), so patience is the key here; otherwise, you miss the boat… I was testing a 10k share purchase earlier on a fairly slow run up, and I had trouble getting it filled… imagine when news hits. Whether you are in at .30c, .50c, or .70c is irrelevant in the grander scheme of things. Patience and confidence my friend… we are in position for a great opportunity.
We are all investing in the most important drug of the decade. Don't let the small stuff bother you. It will appear we are experiencing large, unpredictable, scary swings in price, but when official PR hits, all of that will become insignificant. Have confidence in the known... we've all seen the pre-print. We know what we have here. Its just a matter of time.
RLFTF needs about $20M more to complete all current trials, including the inhaler trials. They only have about $3M in the bank, so they do indeed need money to complete trials and begin ramping up production. They do have access to liquidity via GEM; however, they may already have enough to complete trials with their new Princeton Angels onboard :)
BTW... I think it would be in all of our best interests to not bring attention to that recent funding... and we should not be rocking to boat regarding market maker manipulation. Let's just let the powerful do what they need to do to get this thing off the ground for us. Complain later please.
I dont understand why RLF on the Swiss market isn't pop'n. The current price is less than our close yesterday. Are they still in pre-market or something? Any thoughts?
Assuming Covid is the only application.
Hey guys... I'm new here. Been watching your posts for the past couple weeks from the outside and finally decided to join, as you guys all work well together and I'd like to be a part of the team. btw... great dd you guys have done on this stock! Looking forward to helping.
Uncle Gee Gee
RLFTF 50k shares